View Older Stories View More Recent Stories

Jan 26, 2024 12:25PM ROSEN, LEADING INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALVR
Jan 23, 2024 12:07PM ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALVR
Nov 16, 2023 07:00AM AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
Aug 28, 2023 07:00AM AlloVir to Present at Upcoming Investor Conferences
Aug 3, 2023 07:00AM AlloVir Reports Second Quarter 2023 Financial Results
Jun 5, 2023 07:00AM AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant C
May 16, 2023 07:04AM AlloVir (ALVR) Appoints Cintia Piccina as Chief Commercial Officer
May 16, 2023 07:00AM AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
May 4, 2023 07:00AM AlloVir Reports First Quarter 2023 Financial Results
May 1, 2023 07:00AM AlloVir to Present at the BofA Securities 2023 Health Care Conference
Apr 26, 2023 07:00AM AlloVir (ALVR) Presents Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study
Apr 26, 2023 07:00AM AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
Feb 23, 2023 04:16PM AlloVir (ALVR) Appoints Derek Adams to its Board
Feb 23, 2023 04:15PM AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
Feb 15, 2023 07:07AM AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
Feb 15, 2023 07:00AM AlloVir (ALVR) Reports Positive Final Results from Phase 2 Study of Posoleucel
Feb 15, 2023 07:00AM AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
Feb 1, 2023 07:00AM AlloVir to Participate in the SVB Securities Global Biopharma Conference
Jan 9, 2023 07:00AM AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
Jan 3, 2023 07:00AM AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 10, 2022 05:15PM AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
Nov 15, 2022 07:00AM AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 3, 2022 09:07AM Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
Nov 3, 2022 07:00AM AlloVir Reports Third Quarter 2022 Financial Results
Aug 31, 2022 07:00AM AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 4, 2022 07:00AM AlloVir Reports Second Quarter 2022 Financial Results
Jul 27, 2022 07:00AM AlloVir (ALVR) Announces 27.5M Share Offering at $4.61/sh
Jul 27, 2022 07:00AM AlloVir Announces $126.6 Million Registered Direct Offering
Jun 7, 2022 08:32AM AlloVir (ALVR) Reports Prelim Phase 2 Data Supporting the Ongoing Study of Posoleucel
Jun 7, 2022 08:30AM AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
May 5, 2022 07:00AM AlloVir Reports First Quarter 2022 Financial Results
Apr 20, 2022 07:00AM AlloVir (ALVR) Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel
Apr 20, 2022 07:00AM FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell
Mar 31, 2022 07:02AM AlloVir (ALVR) Appoints Shawn Tomasello to Its Board
Mar 31, 2022 07:00AM AlloVir Appoints Shawn Tomasello to Its Board of Directors
Mar 22, 2022 07:00AM AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant P
Feb 11, 2022 07:00AM AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Feb 10, 2022 07:00AM AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
Jan 5, 2022 07:30AM AlloVir (ALVR) Announces FDA Grants RMAT Designation to Posoleucel for Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
Jan 5, 2022 07:30AM FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transpl
Jan 3, 2022 04:05PM AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 16, 2021 04:05PM AlloVir (ALVR) Announces Departure of Chief Medical Officer
Dec 16, 2021 04:05PM AlloVir Announces Departure of Chief Medical Officer Augustin Melian
Dec 13, 2021 05:15AM AlloVir (ALVR) Reports Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study
Dec 11, 2021 01:00PM AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
Dec 2, 2021 04:05PM AlloVir to Host Virtual Investor Event
Nov 15, 2021 07:00AM AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nov 5, 2021 07:00AM AlloVir Reports Third Quarter 2021 Financial Results
Oct 4, 2021 07:03AM AlloVir (ALVR) Granted FDA Orphan Drug Designation for Posoleucel
Oct 4, 2021 07:00AM FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
View More Recent Stories View Older Stories